Loading...
Loading...
MORF| Name | Value |
|---|---|
| Revenues | 60.2M |
| Cost of Revenue | 0.3M |
| Gross Profit | 60.0M |
| Operating Expense | 45.3M |
| Operating I/L | -45.3M |
| Other Income/Expense | 6.4M |
| Interest Income | 6.4M |
| Pretax | -38.9M |
| Income Tax Expense | 0.1M |
| Net Income/Loss | -39.0M |
Morphic Holding, Inc. is a biopharmaceutical company specializing in the discovery and development of oral small-molecule integrin therapeutics for autoimmune, cardiovascular, metabolic diseases, fibrosis, and cancer. Its lead product candidates include MORF-057, targeting inflammatory bowel disease and idiopathic pulmonary fibrosis, and avß6 and avß8 for fibrotic diseases and solid tumors, respectively. The company generates revenue through the development and commercialization of these integrin-based therapeutics. Additionally, Morphic has research collaborations with Engitix Ltd and Schrödinger, LLC, as well as license and collaboration agreements with various organizations to further its product development and commercialization efforts.
